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Abstract: In patients with chronic obstructive pulmonary disease (COPD), moderate or severe pulmonary
hypertension (COPD-PH) is associated with increased rates of morbidity and mortality. Despite this, ap-
proaches to treatment and the efﬁcacy of phosphodiesterase type 5 inhibition (PDE-5i) in COPD-PH are
unresolved. We present the clinical rationale and study design to assess the effect of oral tadalaﬁl on
exercise capacity, cardiopulmonary hemodynamics, and clinical outcome measures in COPD-PH patients.
Male and female patients 40–85 years old with GOLD stage 2 COPD or higher and pulmonary hyperten-
sion diagnosed on the basis of invasive cardiac hemodynamic assessment (mean pulmonary artery pres-
sure [mPAP] >30 mmHg, pulmonary vascular resistance [PVR] >2.5 Wood units, and pulmonary capillary
wedge pressure ≤18 mmHg at rest) will be randomized at a 1∶1 ratio to receive placebo or oral PDE-5i
with tadalaﬁl (40 mg daily for 12 months). The primary end point is change from baseline in 6-minute
walk distance at 12 months. The secondary end points are change from baseline in PVR and mPAP at
6 months and change from baseline in peak volume of oxygen consumption (V
:
o2) during exercise at
12 months. Changes in systemic blood pressure and/or oxyhemoglobin saturation (SaO2) at rest and during
exercise will function as safety outcome measures. TADA-PHiLD (TADAlaﬁl for Pulmonary Hypertension
assocIated with chronic obstructive Lung Disease) is the ﬁrst sufﬁciently powered randomized clinical trial
testing the effect of PDE-5i on key clinical and drug safety outcome measures in patients with at least
moderate PH due to COPD.
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INTRODUCTION
Pulmonary hypertension (PH) is the clinical phenotype
that results from adverse remodeling of distal pulmonary
arterioles in the setting of genetic or acquired perturba-
tions to cell-signaling pathways responsible for maintain-
ing normal pulmonary vascular function.
1 The prepon-
derance of clinical trials in this disease have investigated
the effect of pulmonary circulation–speciﬁc pharmacother-
apy on outcome in patients with World Health Organiza-
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[PAH], formerly referred to as “primary pulmonary hy-
pertension”); however, PAH is exceedingly rare in com-
parison to other clinically important forms of PH.
2 For
example, chronic obstructive pulmonary disease (COPD),
which afﬂicts ˜46 million Americans and is responsible
for a substantial economic burden on the US healthcare
system,
3,4 is an important promoter of PH. Indeed, mod-
erate or severe PH is increasingly recognized as a pivotal
risk factor that is associated with clinical worsening
5 and
early mortality
6 in patients with COPD despite optimal
standard of care therapy (i.e., supplemental oxygen). Taken
together, these observations underscore the importance
of identifying effective pharmacotherapies to improve car-
diopulmonary hemodynamics and clinical outcome in pa-
tients with PH associated with COPD (COPD-PH).
RATIONALE
PH due to chronic obstructive lung disease
The pathobiological mechanism(s) underpinning clinical
expression of PH in WHO group 3 PH and, speciﬁcally,
COPD-PH appear to be related to the effects of chronic
alveolar hypoxia on the development of pulmonary en-
dothelial dysfunction, pulmonary vasoconstriction, and pul-
monary vascular remodeling (concentric medial hypertro-
phy and muscularization of distal pulmonary arterioles).
The destruction of alveolar-capillary units, in turn, results
in decreased pulmonary vascular bed cross-sectional area
and attendant clinical consequences, including lung hy-
perinﬂation, dyspnea, and diminished functional capac-
ity (reviewed in Chaouat et al.
7). Longitudinal increases
in pulmonary vascular resistance and pressure promotes
maladaptive changes to right ventricular (RV) geometry
and function and, ultimately, right heart failure (cor
pulmonale) that is associated with elevated rates of COPD-
PH-associated morbidity and premature death.
8
Clinical trials have established that long-term oxygen
therapy (LTOT) is an effective strategy by which to im-
prove clinical outcome and decrease mortality in patients
with hypoxemia and chronic obstructive lung disease.
9,10
However, the absolute risk reduction for adverse clinical
events or mortality attributable to LTOT in COPD is mod-
erate and limited only to a subset of the overall population
with COPD-PH. Moreover, a paucity of clinical data exist
in support of LTOT as an effective therapy by which to
attenuate pulmonary vascular complications of COPD, de-
spite the important clinical implications of comorbid PH
on quality of life and outcome in the COPD-PH patient
population. To the contrary, evidence suggests that the pres-
ence of PH in COPD is associated with poor survival and
increased hospitalizations despite the initiation of LTOT.
11
Collectively, these observations illustrate the importance
of assessing the efﬁcacy of pulmonary circulation–speciﬁc
pharmacotherapies to abrogate pulmonary vascular remod-
eling and PH in COPD-PH.
Hypoxia and nitric oxide (NO
•)–cyclic guanosine
monophosphate (cGMP) signaling in pulmonary
blood vessels
By inhibiting the degradation of cGMP, phosphodiester-
ase type 5 inhibitors (PDE-5i) increase bioactive levels of
the potent pulmonary vasodilator and antimitogenic mole-
cule NO
• (Fig. 1). In experimental animal models of PAH
and in humans with this disease, pulmonary vascular dys-
function is linked to increased PDE-5 and decreased NO
•
levels in pulmonary blood vessels and RV cardiomyo-
cytes.
12 We and others have demonstrated previously that
levels of the major NO
• metabolite, nitrite (NO2
−), are de-
creased in lung tissue harvested from pulmonary hyper-
tensive rats exposed to chronic hypoxia, which, in turn, is
associated with pulmonary vascular remodeling and dys-
function.
13,14 Numerous potential mechanisms exist by
which to account for the observation that pulmonary vas-
cular levels of bioavailable NO
• are decreased in the set-
ting of chronic hypoxia, including the adverse effects of
increased pulmonary vascular oxidant stress on NO
• sens-
ing by soluble guanylyl cyclase (which is the chief biolog-
ical source of cGMP),
15 consumption of NO
• by elevated
levels of pulmonary vascular reactive oxygen species,
16 or
diminished endothelin receptor type B–dependent NO
•
synthesis,
13 among others.
17 Together, these observations
provide biological plausibility to the assertion that restor-
ing cGMP levels in pulmonary vascular tissue through
PDE-5i may be an important and as yet underutilized treat-
ment in COPD-PH.
The clinical effects of targeting NO
• signaling in
COPD-PH patients
The potential therapeutic value of targeting NO
• signaling
in patients with COPD has been suggested by previous
studies.
11,18,19 In one prospective, randomized controlled
trial, the effect of pulsed inhaled nitric oxide (iNO) ther-
apy for 12 weeks on cardiopulmonary hemodynamics was
compared with placebo in COPD patients with mild PH
receiving chronic oxygen supplementation. In that study,
iNO decreased mean pulmonary artery pressure (mPAP)
and indexed pulmonary vascular resistance (PVR) signiﬁ-
cantly.
11 Moreover, several small clinical studies have
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PH.
20,21 Madden et al.
21 demonstrated that sildenaﬁl
(50 mg daily for 8 weeks) improved PVR (mean decrease
of 3.2 Wood units) in 16 patients with WHO group 3 PH
(due to lung disease). However, this and other
22,23 pub-
lished trials investigating PDE-5i in the treatment of
COPD-PH were of short duration and lacked adequate sta-
tistical power to assess changes in clinically relevant func-
tional outcomes. Hence, the acceptance of PDE-5i into
routine clinical practice for COPD-PH has been limited by
a lack of sufﬁciently powered randomized clinical trials. In
addition, there are safety concerns in patients with COPD
regarding the potential for pulmonary vasodilator thera-
pies to exacerbate ventilation/perfusion (V
:
=Q
:
) mismatch
and augment hypoxemia.
19 Results from the planned
TADA-PHiLD (TADAlaﬁl for Pulmonary Hypertension
assocIated with chronic obstructive Lung Disease) trial
will address these previous limitations and provide a rigor-
ous examination of the efﬁcacy and safety limitations of
PDE-5i in patients with COPD-PH.
STUDY DESIGN
The TADA-PHiLD study is a multicentered (Providence
Veterans Affairs Medical Center, Veterans Affairs Boston
Healthcare System, and Veterans Affairs Greater Los Ange-
les Healthcare System), prospective, randomized, placebo-
controlled, double-blind clinical trial comparing oral tadala-
ﬁl (40 mg daily) to placebo to assess changes in functional
capacity, cardiopulmonary hemodynamics, and echocar-
diographically assessed RV function in patients with at
least moderate PH due to COPD (NCT01862536 at http://
www.clinicaltrials.gov). The objective of the study is to de-
ﬁne the therapeutic efﬁcacy and safety proﬁle of PDE-5i
in COPD-PH. Moreover, the overall clinical proﬁle of PH
Figure 1. Adverse effects of hypoxia
on normal nitric oxide (NO
•)–cyclic
guanosine monophosphate (cGMP)
signalinginpulmonaryarterysmooth
muscle cells. Upregulation of various
pathobiological signaling intermedi-
aries in the pulmonary vasculature
by hypoxia may result in increases
inpulmonaryvascularinﬂammation,
endothelin1(ET-1),andoxidantstress
levels, which, in turn, promote pul-
monary vasoconstriction and adverse
remodeling of pulmonary arterioles.
This may occur, in part, through the
consumptionofNO
•byoxidantstress
and/or oxidation of soluble guanylyl
c y c l a s e( s G C )a tt h ep r o s t h e t i ch e m e
ligand or functional protein cysteinyl
thiols (i.e., Cys-122) that are neces-
sary for normal NO
•-sGC signal-
ing. By inhibiting phosphodiester-
ase type 5 (PDE-5) in pulmonary
blood vessels (and right ventricu-
lar cardiomyocytes), tadalaﬁl atten-
uates degradation of cGMP, which
functions as a key secondary mes-
senger necessary to maintain nor-
mal pulmonary vascular tone and
prevent vascular remodeling. eNOS:
endothelial nitric oxide synthase;
PSMC: pulmonary smooth muscle
cell; iNOS: inductable nitric oxide
synthase; GTP: guanosine triphos-
phate. Adapted with permission
from Francisetal.
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proﬁle of patients encountered in actual practice: this study
aims to investigate the effect of tadalaﬁl for COPD-PH un-
der “real-world” conditions in order to inform practitioners
regarding the safety proﬁle and potential relevance of this
therapy to patients encountered clinically. Results from this
trial are anticipated to aid in characterizing the appropriate-
ness of PDE-5i therapy in this disease and may inform fu-
ture larger randomized clinical trials that promote PDE-5i
at alternative doses and/or as part of a combination therapy
for COPD-PH.
Patient selection and randomization
A complete list of inclusion and exclusion criteria is pro-
vided in Table 1 and Figure 2. These criteria will be used
to identify patients with at least moderate COPD and mod-
erate to severe PH. The rationale for selecting these crite-
ria was based, in part, on reports in the literature and from
retrospectively analyzed pilot data from our own clinical
experience (unpublished) indicating that mild to moder-
ately elevated pulmonary artery pressure is associated with
recurrent hospitalization, decreased quality of life, and
shortened life span in COPD.
5,24,25 Although COPD is the
predominate phenotype anticipated for inclusion in this
study, the possibility exists that patients with overlap syn-
dromes involving pulmonary ﬁbrosis and chronic emphy-
sema syndrome (CPFE) or COPD and concomitant ob-
structive sleep apnea (OSA), referred to as COPD/OSA,
may also be included (Table 1). In patients with CPFE
and/or COPD/OSA, the contribution of PH to the clinical
expression of these disease phenotypes is suggested by the
presence of dyspnea, hypoxemia, and decreased diffusion
capacity of the lungs for carbon monoxide that are “out of
proportion” to the degree of airﬂow obstruction assessed
by standard pulmonary function testing.
26,27 Nevertheless,
patients with OSA or CPFE as the central mechanism for
PH will be identiﬁed on the basis of apnea/hypoxia in-
dex >15 and the presence of substantial lung ﬁbrosis on
thoracic computed tomography, respectively, and excluded
from study enrollment.
Only patients meeting the following criteria will be con-
sidered for trial enrollment: (i) GOLD stage 2 COPD or
Table 1. Patient selection criteria for the TADA-PHiLD (TADAlaﬁl for Pulmonary Hypertension assocIated with
chronic obstructive Lung Disease) trial
Inclusion criteria Exclusion criteria
Male and female patients
40–85 years old
History of WHO group 1, 2, 4, or 5 PH
Systemic hypotension (systolic blood pressure <90 mmHg on ≥2
ambulatory measurements) At least GOLD stage 2 COPD
assessed by PFT:
a
• FEV1 <80% predicted and
• FEV1/FVC <0.70
Child-Pugh B or C hepatic impairment
Severe renal insufﬁciency (GFR <30 mL/min/1.73 m
2)
Severe aortic stenosis (AVA <1.0 cm
2)
PH by RHC:
b
• mPAP >30 mmHg and
• PVR >2.5 WU and
• PCWP ≤18 mmHg
History of unstable angina, recent myocardial infarction, or stroke (<6 months)
Untreated hypoxemia at rest (SaO2 <92%)
Severe hypoxemia at rest requiring supplemental O2 ≥4 L/min
Diffusion capacity of CO <30% predicted
Known baseline 6-minute walk distance <50 m
Pregnant or breast-feeding women
Moderate or severe obstructive sleep apnea (AHI >15)
Inability to comply with trial tests or a contraindication to tadalaﬁl use, including
anatomical deformations of the penis, sickle cell anemia, multiple myeloma, leukemia,
bleeding disorders, active peptic ulcer disease, retinitis pigmentosa or other retinal
disorders; use or anticipated use of any of the following drugs: nitrate or derivative
medication, protease inhibitor, antifungal agent, rifampin, prazosin, and doxazosin
Note: WHO: World Health Organization; PH: pulmonary hypertension; COPD: chronic obstructive pulmonary disease; FEV1:
forced expiratory volume in the ﬁrst second of expiration; FVC: forced vital capacity; RHC: right heart catheterization; mPAP:
mean pulmonary artery pressure; PVR: pulmonary vascular resistance; WU: Wood unit; PCWP: pulmonary capillary wedge pres-
sure; GFR: glomerular ﬁltration rate; AVA: aortic valve area; SaO2: oxyhemoglobin saturation; AHI: apnea-hypoxia index.
a Performed within 12 months of randomization.
b Performed within 6 month of randomization.
892 | Tadalaﬁl for PH from COPD Maron et al.higher, deﬁned as forced expiratory volume in the ﬁrst sec-
ond of expiration (FEV1)/forced vital capacity <0.70 and
FEV1 <80% predicted by pulmonary function testing done
within 12 months of recruitment, and (ii) PH documented
by invasive hemodynamic assessment (right heart cathe-
terization) to diagnose PH within 6 months of TADA-
PHiLD screening according to the following hemody-
namic criteria: mPAP >30 mmHg, PVR >2.5 Wood units,
and pulmonary capillary wedge pressure ≤18 mmHg at
rest. Compared with the currently available WHO hemody-
namic deﬁnition of PH, our inclusion criteria uses a
higher mPAP, which was selected to increase the speciﬁc-
ity for identifying patients with at least moderate COPD-
PH. Along these lines, we selected a pulmonary capillary
wedge pressure threshold of 18 mmHg owing to recently
published observations indicating that among patients with
Figure 2. TADA-PHiLD (TADAlaﬁl for Pulmonary Hypertension assocIated with chronic obstructive Lung Disease) patient enroll-
ment strategy. Potential study candidates are recruited through echocardiogram (ECHO) database analysis or clinical encounter at
the Veterans Affairs (VA) Boston Healthcare System (Boston, MA), the Providence VA Medical Center (Providence, RI), or the VA
Greater Los Angeles Healthcare System (Los Angeles, CA). For patients meeting study inclusion/exclusion criteria, the etiology of
pulmonary hypertension (PH) is adjudicated by a cardiologist and a pulmonologist experienced in the clinical management of PH.
Patients may exit the study algorithm voluntarily, in the absence of World Health Organization (WHO) group 3 PH, due to
tadalaﬁl intolerance, or by virtue of clinical worsening, which is deﬁned as systemic hypotension, worsening hypoxemia, adverse
drug event, or hospitalization requiring intensive care unit level of care. COPD: chronic obstructive pulmonary disease; FEV1:
forced expiratory volume in the ﬁrst second of expiration; FVC: forced vital capacity; PASP: pulmonary artery systolic pressure;
PFT: pulmonary function testing; RHC: right heart catheterization; mPAP: mean pulmonary artery pressure; PVR: pulmonary
vascular resistance; WU: Wood unit; PCWP: pulmonary capillary wedge pressure; V
:
=Q
:
: ventilation/perfusion; CT: computed
t o m o g r a p h y ;W H O :W o r l dHealth Organization.
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is associated with increased mortality compared with PH
patients with pulmonary capillary wedge pressure (PCWP)
<15 mmHg, and, thus, this clinical proﬁle may represent a
cohort of patients most likely to beneﬁt from the study drug
therapy.
28
To decrease the probability that patients are enrolled
with non–WHO group 3 PH or pulmonary ﬁbrosis as
the likely central mediator of dyspnea, a comprehensive
clinical review will be performed for each candidate that
includes analysis of liver function tests; HIV status; re-
nal function; review of chest imaging, including prior
computed tomography (CT) of the thorax and ventila-
tion/perfusion scan; sleep study; and echocardiography.
Randomization will occur by computer-generated num-
ber assignment.
Tadalaﬁl administration and dose selection
Tadalaﬁl was selected for investigation owing to its phar-
macokinetic proﬁle (t1/2 of 17.5 hours; mean oral clear-
ance of 2.48 L/h)
29 that favors once-daily dosing and, thus,
drug adherence. Tadalaﬁl is not currently approved for the
treatment of WHO group 3 PH; however, a Food and
Drug Administration off-label exemption was provided for
the use of tadalaﬁl in the TADA-PHiLD trial. Following
randomization, study participants will then receive a test
dose of the study medication (20 mg of tadalaﬁl or pla-
cebo) and observed for 4 hours to ensure that blood pres-
sure and oxygen levels are not affected adversely by the
medication. Study participants who develop systemic hy-
potension (deﬁned as a decrease in systolic blood pressure
to <90 mmHg or a fall in systolic blood pressure of
>20 mmHg accompanied by symptoms such as dizziness
or syncope), hypoxemia (deﬁned as a decrease in oxyhemo-
globin saturation [SaO2] to <90% or a requirement for in-
creased basal oxygen supplementation levels to >4 L/min),
or other evidence of drug intolerance during the study
drug test phase will not participate further in the study.
Owing to the possibility that PDE-5i may inﬂuence ad-
versely patients’ V
:
=Q
:
proﬁle, the tadalaﬁl dose will be in-
creased from 20 to 40 mg daily as clinically tolerated over
the course of the study duration rather than according to a
predetermined schedule per se.
Study visits and procedure schedule
The schedule for patient follow-up, including procedures
to be performed during the study period, are outlined in
Table 2. These assessments are divided into the following
categories related to tadalaﬁl treatment: safety (i.e., pa-
tient contact, medical history, physical examination, med-
ication adherence, clinical exacerbation history, adverse
event monitoring), exercise response (6-minute walk dis-
tance [6MWD], cardiopulmonary exercise test), symptom
and quality-of-life response (dyspnea and health-related
quality-of-life surveys), and cardiopulmonary and bio-
chemical response (echocardiography, right heart cathe-
terization, plasma N-terminal brain natriuretic peptide
concentration). The time interval for each benchmark as-
sessment is based on prudence in the case of safety and
predicted time to clinical response to tadalaﬁl for the other
measures, which was derived from prior clinical studies
involving PDE-5i and PH patients.
30-32
Sample size determination and clinical end points
The primary clinical end point is the effect of tadalaﬁl on
exercise capacity, as measured by change in 6MWD from
baseline at 12 months. The secondary clinical end points
are change from baseline in PVR and mPAP at 6 months
and change from baseline in maximal volume of oxygen
extraction (V
:
o2) during exercise at 12 months. Change in
peak V
:
o2 from baseline was selected as an end point owing
to recently reported ﬁndings identifying this as a clinically
relevant measure that correlates positively with improved
exercise tolerance and quality of life in patients with PH.
33
We selected a time point from randomization to repeat
right heart catheterization of 6 months, which we believe
is within the time required to demonstrate meaningful
cardiopulmonary hemodynamic improvement following
study drug therapy, in order to ensure that potential study
attrition at longer enrollment intervals does not limit suf-
ﬁcient collection of PVR/mPAP data. These end points
are intended to reﬂect the consequences of drug-induced
changes to pulmonary vascular remodeling, cardiopul-
monary hemodynamics, aerobic conditioning, and func-
tional capacity and will allow comparisons to results of
previous PH trials using this class of drug.
31,32
The principal investigator of this study will serve as the
sole keeper of all data relevant to the TADA-PHiLD study.
We propose to analyze continuous measures compared
between two independent groups; thus, power and sam-
ple size calculations are derived from a simple two-sample
t test. A sample size of 60 subjects in each group (account-
ing for an estimated 20% dropout rate from a total enroll-
ment of 150 patients) would result in a general effect size
of 0.60 standard deviation [SD] units using an α =0 . 0 5
and 90% power. Determination of predicted SD for
change in 6MWD was calculated from Lewis et al.,
31 who
studied the effects of sildenaﬁl on persons with WHO
group 2 PH attributable to left ventricular systolic heart
failure. On the basis of their report, we predict in our
894 | Tadalaﬁl for PH from COPD Maron et al.study the SD of change in 6MWD to be 51 m, which is
comparable to or greater than clinically important differ-
ences reported previously for 6MWD in patients with
COPD.
34,35 Analyses involving change in 6MWD will be
controlled to account for the potentially confounding ef-
fect of change in supplemental oxygen level on functional
capacity.
A similar statistical strategy was utilized to calculate
the number of patients needed to maintain sufﬁcient
power with respect to our secondary clinical end points.
From Galie ` et al.,
36 who studied the effects of sildenaﬁl
in persons with idiopathic PAH, we obtained the SD of
change in PVR (447.1 dyn·s·cm
5) and mPAP (8.6 mmHg)
that was attributable to treatment at 12 weeks. On the ba-
sis of these values, we anticipate detecting a difference of
−264 dyn·s·cm
5 and −5.2 mmHg for PVR and mPAP,
respectively, which are within the range reported previ-
ously as clinically meaningful changes in response to PH
treatment.
Other outcomes that will be assessed include differ-
ences between the two study groups in rates of (i) acute
COPD exacerbations (deﬁned as increased dyspnea, in-
creased sputum volume, and increased sputum purulence
for at least 3 days and requiring treatment with systemic
corticosteroids or antibiotics and emergency department
visit or hospitalization) and (ii) pulmonary and all-cause
hospitalizations. Additional outcome measures include dif-
ferences in the following echocardiographically validated
indices of RV structure/function: right atrial, left atrial,
and RV dimensions; pulmonary artery acceleration time;
and presence (or absence) and shape of a systolic “notch”
in the RV outﬂow-tract Doppler proﬁle.
37
All cardiac catheterization and cardiopulmonary exer-
cise test data will be interpreted at a central core labora-
tory. All echocardiography data will be interpreted by an
expert echocardiographer with substantial experience in
the analysis of PH/RV echocardiographic views.
Drug safety outcome measures
To assess the effect of tadalaﬁl on ventilation/perfusion
status, SaO2 levels and change in supplemental oxygen
requirements will be assessed at rest and on ambulation
during each of the six scheduled 6MWD tests. In addition,
to assess other measures of exercise capacity, cardiopul-
monary exercise testing will be conducted at baseline and
at month 12. Escape criteria (i.e., progressive clinical wors-
ening) meriting temporary withholding of the study drug
and/or withdrawal from TADA-PHiLD may be achieved
by any of the following events: sustained decrease in SaO2
levels to <90% that is not resolved by (increased) supple-
mental oxygen therapy, decreased systolic blood pressure
to <90 mmHg detected by two consecutive ambulatory
blood pressure measurements or a single measurement
in the setting of symptomatic hypotension, the develop-
ment of a major adverse drug reaction, or hospitalization
requiring intensive care unit level of care.
Table 2. Follow-up clinic visits, telephone calls, and schedule of studies
Month
Initial or preenrollment Day 3 1369 1 2
Contact Clinic Tel Clinic Clinic Clinic Clinic Clinic
Medical history/physical examination X XXXXX
Assess medication compliance X X XXXXX
6-minute walk test X XXXXX
Echocardiogram X X
Noninvasive CPET X X
HRQL dyspnea questionnaires X XXXXX
BNP X X X
RHC X X
Exacerbation history
a X XXXXX
Adverse event monitoring X X XXXXX
Note: Tel: telephone contact; CPET: cardiopulmonary exercise test; HRQL: health-related quality of life; BNP: N-terminal brain
natriuretic peptide concentration; RHC, right heart catheterization.
a Exacerbation history is deﬁned as increased dyspnea, increased sputum volume, and increased sputum purulence for at least
3 days requiring treatment with systemic corticosteroids and/or antibiotics and/or emergency department visit or hospitalization.
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PH is increasingly recognized as a key predictor of poor
outcomes in patients with COPD, including hospitali-
zation and premature death. However, standard-of-care
therapy, including supplemental oxygen, appears to be
insufﬁcient to abrogate pulmonary vascular remodeling
and PH in this patient population. The TADA-PHiLD
trial is a multicenter, prospective, randomized, placebo-
controlled, double-blind clinical trial that aims to charac-
terize the efﬁcacy and safety proﬁle of PDE-5i in patients
with chronic obstructive lung disease and moderate to
severe PH.
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